In a victory for Johnson & Johnson, a Philadelphia judge ruled that CEO Alex Gorsky cannot be called as a witness by the plaintiff, who was prescribed Risperdal at the age of five and began growing breasts when he was 12. The trial is the second of approximately 400 trials regarding Risperdal, a drug that has figured prominently in Gorsky’s career.
© 2024 Mad in America Foundation
Ahhhh,Johnson and Johnson the ‘baby care people’.
Risperdal reproached!
The same mealy-mouthing evasion played out with Eli Lilly Zyprexa scandal.
The ‘man in charge’ during the Eli Lilly *viva Zyprexa* scandal was current Indiana governor Mitch Daniels.
The ‘atypical’ antipsychotics-Risperdal,Zyprexa,Seroquel… are essentially reformulated 50 year old Thorazine at 10-30 x’s the price.Zyprexa was hailed as, ‘the most successful drug in the history of neuroscience’.
How can that be legitimate as the conditions the drugs are approved for are only 1% of the population?
Zyprexa especially was ‘pushed’ off-label and made Eli Lilly $67 billion to date.
–Daniel Haszard ‘tell the truth don’t be afraid’ http://www.zyprexa-victims.com
Report comment
Zyprexa , all the “fun” of an anti-psychotic followed by the typical withdrawal reactions of a benzodiazepines like panic attacks plus months of nausia, vommiting and some psychosis thrown in for a bonus. Burn in hell e-lilly .
Now I see that searching “risperdal withdrawal symptoms” results in pages and pages of “help me” posts from people getting sick. When I did the “zyprexa sickness” there wasnt much online yet.
Report comment
This is old news but,
“Drug Maker Told Studies Would Aid It, Papers Say
An influential Harvard child psychiatrist told the drug giant Johnson & Johnson that planned studies of its medicines in children would yield results benefiting the company, according to court documents dating over several years that the psychiatrist wants sealed.
The psychiatrist, Dr. Joseph Biederman, outlined plans to test Johnson & Johnson’s drugs in presentations to company executives. One slide referred to a proposed trial in preschool children of risperidone, an antipsychotic drug made by the drug company. The trial, the slide stated, “will support the safety and effectiveness of risperidone in this age group.”
Dr. Biederman was the lead author of a trial published last year concluding that treatment with risperidone improved symptoms of attention deficit and hyperactivity disorder in bipolar children.
Dr. Biederman — who was director of the Johnson & Johnson Center for Pediatric Psychopathology Research at Massachusetts General Hospital, in Boston — is in the middle of two controversies: one involves the use of antipsychotic drugs in children, and the other relates to conflicts of interest in medicine.
He is the world’s most prominent advocate of diagnosing bipolar disorder in even the youngest children and of using antipsychotic medicines to treat the disease, but much of his work has been underwritten by drug makers for whom he privately consults. An inquiry by Senator Charles E. Grassley, Republican of Iowa, revealed last year that Dr. Biederman earned at least $1.6 million in consulting fees from drug makers from 2000 to 2007 but failed to report all but about $200,000 of this income to university officials. ”
The rest of the story is here: http://www.nytimes.com/2009/03/20/us/20psych.html?_r=0
Dr. Biederman’s work helped to fuel a fortyfold increase from 1994 to 2003 in the diagnosis of pediatric bipolar disorder and a rapid rise in the use of powerful, risky and expensive antipsychotic medicines in children…
Report comment